SKI Market

A+| A| A-|

Indian Indices

Sensex

76,631.65 -931.25
( -1.20%)

Global Indices

Nasdaq

47,935.11 1,329.65
(2.85%)

Dow Jones

6,804.45 166.60
(2.51%)

Hang Seng

55,958.99 -349.43
(-0.62%)

Nikkei 225

10,596.41 247.62
(2.39%)

Forex

USD-INR

92.90 -0.03
(-0.03%)

EUR-INR

107.45 0.22
(0.21%)

GBP-INR

123.16 0.23
(0.18%)

JPY-INR

0.58 0.00
(-0.10%)

YOU ARE HERE :
HOME
Markets
Equity
Company News Details

EQUITY - MARKET SCREENER

Industry :

BSE Code

ISIN Demat

Book Value()

NSE Symbol

P/E(TTM)

Mar.Cap( Cr.)

EPS(TTM)

Face Value()

Div & Yield %

Back

emerald finserv ltd

Natco Pharma receives USFDA EIR report for API unit in Chennai

Feb 13,2026

NATCO Pharma announced that the U.S. Food and Drug Administration (FDA) had conducted an inspection at the Active Pharmaceutical Ingredient Division located in Manali, Chennai from 17 November – 21 November 2025. The Company received seven (7) observation in the Form-483.

Further, the Company has received the EIR (Establishment Inspection Report) from the USFDA on the classification of the above-referred inspection as Voluntary Action Indicated (VAI).

76,631.65 -931.25 ( -1.20%)

47,935.11 1,329.65 (2.85%)

6,804.45 166.60 (2.51%)

55,958.99 -349.43 (-0.62%)

10,596.41 247.62 (2.39%)

92.90 -0.03 (-0.03%)

107.45 0.22 (0.21%)

123.16 0.23 (0.18%)

0.58 0.00 (-0.10%)